Read the findings & sources
Human study discussedA report of six placebo-controlled human studies of AOD9604 examined safety and tolerability. Researchers did not observe an increase in serum IGF-1 or evidence of impaired glucose tolerance in the evaluated studies. These findings describe selected safety measurements over limited follow-up; they do not establish weight-loss efficacy, long-term safety or equivalence between oral and injectable preparations.